# Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)

> **NCT01300455** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 26 (actual)

## Conditions studied

- Sleep Apnea

## Interventions

- **DRUG:** Suvorexant
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT01300455
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-19
- **Primary completion:** 2011-08-11
- **Final completion:** 2011-08-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300455, "Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01300455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*